Beck Bode LLC’s BridgeBio Pharma BBIO Stock Holding History

Beck Bode LLC’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-410,531	Closed	-$10.5M	–	112
2024 Q3	$10.5M	Buy	+410,531	New	+$10.8M	1.97%	25

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Beck Bode LLC's BBIO Position: Q4 2024 in Review

Beck Bode LLC sold out of BridgeBio Pharma (BBIO) in Q4 2024, closing a stake of 410,531 shares — an estimated $10.5M sold.

Beck Bode LLC first reported a position in BBIO in Q3 2024 and held it in 1 quarter. The position peaked at $10.5M in Q3 2024. 263 funds tracked by Wall St. Rank hold BBIO as of Q4 2024.

Beck Bode LLC reported no remaining BridgeBio Pharma position as of Q4 2024 after selling out during the quarter.
Beck Bode LLC sold 410,531 BridgeBio Pharma shares in Q4 2024, an estimated $10.5M.
Beck Bode LLC first reported a position in BridgeBio Pharma in Q3 2024 and held it in 1 quarter.
Beck Bode LLC's BridgeBio Pharma position peaked at $10.5M in Q3 2024.
263 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2024.

Based on Beck Bode LLC's 13F filing for Q4 2024, filed 14 Feb 2025.